Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
284 participants
INTERVENTIONAL
2011-04-07
2020-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness
NCT01350414
Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma
NCT00803088
Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma
NCT02225392
AIR Extension Study - Long-Term Safety of Alair Treated Subjects
NCT00448812
Bronchial Thermoplasty Global Registry
NCT02104856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alair
Alair system
Alair System
Treatment of airways with the Alair System
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alair System
Treatment of airways with the Alair System
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is able to read, understand, and sign a written Informed Consent to participate in the study and able to comply with the study protocol.
3. Subject has asthma and is taking regular maintenance medication that includes:
1. Inhaled corticosteroid (ICS) at a dosage greater than 1000μg beclomethasone per day or equivalent, AND long acting β2-agonist (LABA) at a dosage of ≥80μg per day Salmeterol or equivalent.
2. Other asthma medications such as leukotriene modifiers, or anti-IgE, are acceptable (Subjects on Xolair® must have been on Xolair for greater than 1 year).
3. Oral corticosteroids (OCS) at a dosage of up to, but not greater than 10mg per day are acceptable.\*
4. Subject has a pre-bronchodilator FEV1 of greater than or equal to 60% of predicted.
5. Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack years total smoking history).
6. Subject is able to undergo outpatient (same day) bronchoscopy in the opinion of the investigator or per hospital guidelines.
7. Subject has at least 2 days of asthma symptoms in the last 4 weeks.
8. Subject has an AQLQ score during the baseline period of 6.25 or less.
* NOTE: Subjects on a dosage regimen of 20mg OCS every other day may be included as this is equivalent to an average daily dosage of 10mg.
Exclusion Criteria
2. Over the last 7 days of a 4 week medication stable period, subject requirement for rescue medication use other than for prophylactic use for exercise exceeds an average of:
1. 8 puffs per day of short-acting bronchodilator, or
2. 4 puffs per day of long-acting rescue bronchodilator, or
3. 2 nebulizer treatments per day. At the discretion of the Principal Investigator, subjects considered as unstable on baseline medications may have medications adjusted and re-evaluated after a 4 week medication stabilization period.
3. Subject has a post-bronchodilator FEV1 of less than 65%.
4. Subject has a history of life-threatening asthma, defined by past intubation for asthma, or ICU admission for asthma within the prior 2 years.
5. Subject has 3 or more hospitalizations for exacerbations of asthma in the previous year.
6. Subject has had 4 or more infections of lower respiratory tract (LRTI) requiring antibiotics in the past 12 months.
7. Subject has had 4 or more pulses of systemic corticosteroids (tablets, suspension or injection) for asthma symptoms in the past 12 months.
8. Subject has a known sensitivity to medications required to perform bronchoscopy (such as lidocaine, atropine and benzodiazepines).
9. Subject has other respiratory diseases including emphysema, cystic fibrosis, vocal cord dysfunction, mechanical upper airway obstruction, Churg-Strauss syndrome, and allergic bronchopulmonary aspergillosis (asthma, immediate cutaneous reactivity to A. fumigatus, total serum IgE of \>1000ng/mL, elevated specific IgE and IgG to A. fumigatus with or without evidence of central bronchiectasis).
10. Subject has segmental atelectasis, lobar consolidation, significant or unstable pulmonary infiltrate, or pneumothorax, confirmed on x-ray.
11. Subject currently has clinically significant cardiovascular disease, including myocardial infarction, angina, cardiac dysfunction, cardiac dysrhythmia, conduction defect, cardiomyopathy, or stroke.
12. Subject has a known aortic aneurysm.
13. Subject has significant co-morbid illness such as cancer, renal failure, liver disease, or cerebral vascular disease.
14. Subject has uncontrolled hypertension (\>200mm Hg systolic or \>100mm Hg diastolic pressure).
15. Subject has an implanted electrical stimulation device (e.g., a pacemaker, cardiac defibrillator, or deep nerve or deep brain stimulator).
16. Subject has coagulopathy (INR \> 1.5).
17. Subject has any other medical condition that would make them inappropriate for study participation, in the Investigator's opinion.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Scientific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas S Bowman, MD
Role: STUDY_DIRECTOR
Boston Scientific Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Lung Health Center
Birmingham, Alabama, United States
Yale University Center for Asthma and Airway Disease
New Haven, Connecticut, United States
University of Chicago
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
LSU Health Sciences
New Orleans, Louisiana, United States
St. Elizabeth's Medical Center
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Lahey Clinic
Burlington, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Spectrum Health Hospitals
Grand Rapids, Michigan, United States
HealthPartners Specialty Center, Lung and Sleep Health
Saint Paul, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Duke University
Durham, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
DuBois Regional Medical Center
DuBois, Pennsylvania, United States
Pennsylvania State Hershey
Hershey, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Virginia Medical Center
Charlottesville, Virginia, United States
Pulmonary Associates of Richmond
Richmond, Virginia, United States
Franciscan Research Center (St. Joseph Medical Center)
Tacoma, Washington, United States
MultiCare Pulmonary Specialists
Tacoma, Washington, United States
University of Wisconsin
Madison, Wisconsin, United States
Surrey Memorial Hospital
Surrey, British Columbia, Canada
Vancouver General Hospital, University of British Columbia
Vancouver, British Columbia, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Hospital Laval Centre de Pneumologie
Sainte-Foy, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chupp G, Kline JN, Khatri SB, McEvoy C, Silvestri GA, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Trevor J, Kahlstrom N, Simoff M, Wahidi MM, Lamb CR, Ferguson JS, Haas A, Hogarth DK, Tejedor R, Toth J, Hey J, Majid A, LaCamera P, Fitzgerald JM, Enfield K, Grubb GM, McMullen EA, Olson JL, Laviolette M. Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years: The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma Study. Chest. 2022 Mar;161(3):614-628. doi: 10.1016/j.chest.2021.10.044. Epub 2021 Nov 10.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol and Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Bronchial Thermoplasty
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.